8.65

27.02% 1.84

Alpha Cognition Inc (ACOG)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$6.81

Offen:

$7.15

24-Stunden-Volumen:

669.36K

Relative Volume:

8.71

Marktkapitalisierung:

$138.57M

Einnahmen:

Nettoeinkommen (Verlust:

$-14.72M

KGV:

-3.0565

EPS:

-2.83

Netto-Cashflow:

$-7.41M

1W Leistung:

+16.42%

1M Leistung:

+103.53%

6M Leistung:

+61.09%

1J Leistung:

+0.00%

1-Tages-Spanne:

$6.95

$9.68

1-Wochen-Bereich:

$6.55

$9.68

52-Wochen-Spanne:

$3.75

$9.68

Alpha Cognition Inc Stock (ACOG) Company Profile

Firmenname

Alpha Cognition Inc

Sektor

Healthcare (1170)

Branche

Biotechnology (671)

Telefon

(858) 344-4375

Adresse

1200-750 W PENDER ST, VANCOUVER

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ACOG's Discussions on Twitter

Vergleichen Sie ACOG mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACOG Alpha Cognition Inc	8.65	119.03M	0	-14.72M	-7.41M	-2.83
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-18	Eingeleitet	H.C. Wainwright	Buy

Alpha Cognition Inc Aktie (ACOG) Neueste Nachrichten

08:21 AM

We Think Alpha Cognition (NASDAQ:ACOG) Can Easily Afford To Drive Business Growth - Yahoo Finance

08:21 AM

12:00 PM

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview - BioSpace

May 15, 2025

May 11, 2025

Alpha Cognition (ACOG) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025

May 06, 2025

Alpha Cognition, Inc.’s (NASDAQ:ACOG) Lock-Up Period To Expire on May 12th - Defense World

May 06, 2025

May 02, 2025

Will Alpha Cognition's Recently Launched Alzheimer's Drug Be A Commercial Success? - RTTNews

May 02, 2025

May 01, 2025

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview - BioSpace

May 01, 2025

Apr 30, 2025

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard

Apr 30, 2025

Apr 28, 2025

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Yahoo Finance

Apr 28, 2025

(Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Business Wire

Apr 28, 2025

Apr 14, 2025

Alpha Cognition Inc. Reports Strong 2024 Financials - TipRanks

Apr 14, 2025

Apr 11, 2025

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace

Apr 11, 2025

Apr 10, 2025

Alpha Cognition announces board changes - Investing.com

Apr 10, 2025

Alpha Cognition announces board changes By Investing.com - Investing.com Canada

Apr 10, 2025

Alpha Cognition Appoints Robert Wills To Board - citybiz

Apr 10, 2025

Apr 09, 2025

Alpha Cognition Earnings Call: Positive Outlook Amid Growth - TipRanks

Apr 09, 2025

Apr 08, 2025

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - The Globe and Mail

Apr 08, 2025

Apr 05, 2025

Alpha Cognition stock hits 52-week low at $4.65 amid downturn - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

HC Wainwright Expects Stronger Earnings for Alpha Cognition - Defense World

Apr 04, 2025

Apr 01, 2025

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 - TradingView

Apr 01, 2025

Alpha Cognition (NASDAQ:ACOG) Given Buy Rating at HC Wainwright - Defense World

Apr 01, 2025

Mar 31, 2025